お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:乳癌治療薬:世界の市場および臨床試験の分析 (~2025年)
市場調査レポート
商品コード
920932

乳癌治療薬:世界の市場および臨床試験の分析 (~2025年)

Global Breast Cancer Drug Market & Clinical Trial Insight 2025

出版日: | 発行: PNS Pharma | ページ情報: 英文 1140 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.15円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

乳癌治療薬:世界の市場および臨床試験の分析 (~2025年)
出版日: 2020年01月13日
発行: PNS Pharma
ページ情報: 英文 1140 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の乳癌治療薬の市場は、ワクチン、抗体、小分子、ペプチド、放射性医薬品など各種薬剤クラスの総計で400億米ドルの市場機会と推計されています。

当レポートでは、世界の乳癌治療薬の上市済み製品および臨床パイプラインの動向を調査し、乳癌治療薬の開発の経緯、世界の乳癌有病率・統計、主な上市済み薬、薬剤クラス・フェーズ別の臨床パイプラインの動向、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション:乳癌治療薬市場

  • 概要
  • 開発の経緯

第2章 世界の乳癌有病率・統計

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • ロシア
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第3章 乳癌管理のための上市済み薬

  • ホルモン療法
    • アロマターゼ阻害剤
    • エストロゲン受容体アンタゴニスト
    • 選択的エストロゲン受容体調節薬 (SERM)
    • 性腺刺激ホルモン放出ホルモン薬
  • CDK 4/6阻害剤
  • HER2阻害剤
    • モノクローナル抗体
    • チロシンキナーゼ阻害剤
  • PI3K & mTOR阻害剤
  • PARP阻害剤
  • その他
    • 免疫チェックポイント阻害剤
    • 有糸分裂 / 微小管阻害剤
    • EGFR阻害剤

第4章 乳癌治療薬:臨床分析

  • 概要
  • 乳癌の臨床試験:薬剤クラス・フェーズ別
    • CDK 4/6阻害剤
    • ホルモン療法
    • PARP阻害剤
    • その他の標的治療薬
    • ワクチン・免疫療法
    • HER2阻害剤

第5章 世界の乳癌治療薬:臨床パイプラインの分析

  • フェーズ別
  • 地域・国別
  • バイオマーカー別
  • 配合別
  • 企業別
  • 機序別

第6章 世界の乳癌治療薬臨床試験の分析:状況不明

  • 概要
  • 臨床パイプラインの分析

第7章 世界の乳癌治療薬臨床試験の分析:調査段階

  • 概要
  • 臨床パイプラインの分析

第8章 世界の乳癌治療薬臨床試験の分析:前臨床段階

  • 概要
  • 臨床パイプラインの分析

第9章 世界の乳癌治療薬臨床試験の分析:臨床段階

  • 概要
  • 臨床パイプラインの分析

第10章 世界の乳癌治療薬臨床試験の分析:第I相

  • 概要
  • 臨床パイプラインの分析

第11章 世界の乳癌治療薬臨床試験の分析:第I/II相

  • 概要
  • 臨床パイプラインの分析

第12章 世界の乳癌治療薬臨床試験の分析:第II相

  • 概要
  • 臨床パイプラインの分析

第13章 世界の乳癌治療薬臨床試験の分析:第II/III相

  • 概要
  • 臨床パイプラインの分析

第14章 世界の乳癌治療薬臨床試験の分析:第III相

  • 概要
  • 臨床パイプラインの分析

第15章 世界の乳癌治療薬臨床試験の分析:申請済み

  • 概要
  • 臨床パイプラインの分析

第16章 世界の乳癌治療薬臨床試験の分析:承認済み

  • 概要
  • 臨床パイプラインの分析

第17章 上市済み乳癌治療薬の臨床分析:企業別

第18章 競合環境

  • Novartis
  • Amgen
  • Eli Lilly
  • Merck
  • Pfizer
  • GlaxoSmithKline
  • Roche
  • 武田薬品工業
  • Teva Pharmaceuticals
  • AstraZeneca
  • G1 Therapeutics
  • Nerviano Medical Science
  • Genentech
図表

List of Figures

  • Figure 1-1: Global - Incidence of Breast Cancer by Types (%), 2019
  • Figure 1-2: Global - Number of Total New Diagnosed Cancer Cases vs. Breast Cancer Cases (Million), 2018
  • Figure 1-3: Global - New Cases of Breast Cancer vs. Other Cancers (%), 2018
  • Figure 1-4: Global - Leading Cause of Cancer Related Death (Million), 2018
  • Figure 1-5: Global - Leading Causes of cancer Related Deaths (%), 2018
  • Figure 1-6: Global - Breast Cancer Cases vs. Other Cancers in Females (%), 2018
  • Figure 1-7: Global - Breast Cancer Drug Market Size (US$ Billion), 2019 - 2025
  • Figure 1-8: History of Breast Cancer in Ancient Period
  • Figure 1-9: Breast Cancer before 18th Century
  • Figure 1-10: Historical Development of Breast Cancer Drugs, 19th to 21st Century
  • Figure 2-1: US - Number of Newly Diagnosed Cases of Breast Cancer, 2016-2019 & 2025
  • Figure 2-2: US - Breast Cancer Cases in Women vs. Men, 2019
  • Figure 2-3: US - Breast Cancer Cases Women vs. Men (%), 2019
  • Figure 2-4: US - Breast Cancer Related Deaths in Males & Females, 2019
  • Figure 2-5: US - Probability of Breast Cancer Development in Males & Females (%), 2019
  • Figure 2-6: US - Share of Breast Cancer in Total Newly Diagnosed Cases of Cancer (%), 2019
  • Figure 2-7: US - 10 Year Probability of Female Breast Cancer by Age (%), 2018
  • Figure 2-8: US - States with Highest Breast Cancer Cases, 2019
  • Figure 2-9: US - States with Lowest Breast Cancer Cases, 2019
  • Figure 2-10: US - Breast Cancer Incidence Rate and Death Rate (per 100,000 People), 2011-2015
  • Figure 2-11: US - Current Breast Cancer Age-Specific Incidence Rate and Death Rate (per 100,000 People), 2018
  • Figure 2-12: US - Breast Cancer Incidence Rate by Race & Ethnicity (per 100,000 People), 2011-2015
  • Figure 2-13: US - Breast Cancer Death Rate by Race & Ethnicity (per 100,000 People), 2011-2015
  • Figure 2-14: US - Breast Cancer Incidence Rate by Type (per 100,000 People), 2010-2014
  • Figure 2-15: Canada - Number of Newly Diagnosed Cases of Different Cancers, 2019
  • Figure 2-16: Canada -Newly Diagnosed Cases of Different Cancers (%), 2019
  • Figure 2-17: Canada - Number of Breast Cancer Cases, 2017, 2019 & 2025
  • Figure 2-18: Canada - Number of Female & Male Breast Cancer Cases & Deaths, 2019
  • Figure 2-19: Canada - Breast Cancer Net Survival Rate in Males & Females (%), 2019
  • Figure 2-20: Canada - Female Breast Cancer Cases vs. Other Cancers in Females, 2019
  • Figure 2-21: Canada - Female Breast Cancer Cases vs. Other Cancers in Females (%), 2019
  • Figure 2-22: Canada - Breast Cancer Related deaths vs. Other Cancer Related Deaths in Females (%), 2019
  • Figure 2-23: Canada - Probability of Female Breast Cancer Incidence & Death (%), 2019
  • Figure 2-24: Canada - Breast Cancer Cases by Age (%), 2019
  • Figure 2-25: Canada - Female Breast Cancer Survival Rate by Age, 2019
  • Figure 2-26: Canada - Breast Cancer Cases by Stage (%), 2011-2015
  • Figure 2-27: UK - Number of Breast Cancer Cases, 2016, 2018 & 2025
  • Figure 2-28: UK - Number of Newly Diagnosed Cases of Different Cancers, 2019
  • Figure 2-29: UK - Average Number of Annual Male & Female Breast Cancer Cases, 2018
  • Figure 2-30: UK - Average Breast Cancer Cases by Country, 2018
  • Figure 2-31: UK - Average Breast Cancer Cases by Country (%), 2018
  • Figure 2-32: UK - Total Cancer Cases vs. Breast Cancer Cases in Females, 2018
  • Figure 2-33: UK - Total Cancer Cases vs. Breast Cancer Cases in Females (%), 2018
  • Figure 2-34: UK - Age Specific Incidence & Mortality Rate of Breast Cancer (Per 100,000 Cases), 2018
  • Figure 2-35: Germany - Number of Breast Cancer Cases & Deaths, 2018
  • Figure 2-36: Germany - Number of Newly Diagnosed Cases of Different Cancers, 2018
  • Figure 2-37: Germany - Breast Cancer Cases vs. Other Cancers (%), 2018
  • Figure 2-38: Germany - Breast Cancer Cases vs. Other Cancers Cases in Females (%), 2018
  • Figure 2-39: Germany - Incidence Rate & Death Rate of Breast Cancer (Per 100,000 People), 2018
  • Figure 2-40: Russia - Newly Diagnosed Breast Cancer Cases & Deaths, 2018
  • Figure 2-41: Russia - Newly Diagnosed Cases of Cancer by Types (%), 2018
  • Figure 2-42: Russia - Female Breast Cancer Cases Share in Total Newly Diagnosed Cancer Cases (%), 2017 & 2018
  • Figure 2-43: Russia - Age Specific Incidence & Death Rate of Breast Cancer (Per 100,000 People), 2018
  • Figure 2-44: China - Number of Newly Diagnosed cases of Different Cancers, 2018
  • Figure 2-45: China - Newly Diagnosed Breast Cancer Cases, 2015, 2018 & 2025
  • Figure 2-46: China - Breast Cancer Incidence & Death Rate, 2018
  • Figure 2-47: China - Number of Total Cancer Cases vs. breast cancer Cases in Females, 2018
  • Figure 2-48: China - Total Cancer Cases vs. breast cancer Cases in Females (%), 2018
  • Figure 2-49: China - Age Specific Incidence rate of Breast Cancer (Per 100,000 people), 2015-2019
  • Figure 2-50: India - Breast Cancer Cases, 2015, 2018 & 2025
  • Figure 2-51: India - Number of Breast Cancer Related Deaths, 2015, 2018 & 2025
  • Figure 2-52: India - Newly Diagnosed Cases of Different Type of Cancer (%), 2018
  • Figure 2-53: India - Probability of Breast Cancer Development in Females (%), 2018
  • Figure 2-54: India - Breast Cancer Age-Specific Incidence Rate & Death Rate (Per 100,000 People), 2018
  • Figure 2-55: India - Breast Cancer Cases by Age (%), 2018
  • Figure 2-56: Japan - Breast Cancer Cases, 2014, 2016 & 2018
  • Figure 2-57: Japan - Breast Cancer Related Deaths, 2014 & 2018
  • Figure 2-58: Japan - Newly Diagnosed Cases of Cancer by Type (%), 2018
  • Figure 2-59: Japan - Breast Cancer Cases vs. Other Cancers in Females (%), 2018
  • Figure 2-60: Japan - Age Standardized Breast Cancer Incidence Rate, 2014, 2018 & 2025
  • Figure 2-61: Japan - Age Standardized Breast Cancer Death Rate, 2014 & 2018
  • Figure 2-62: South Korea - Number of Breast Cancer Cases, 2016, 2018 & 2025
  • Figure 2-63: South Korea - Breast Cancer Cases vs. Other Cancers in Women (%), 2018
  • Figure 2-64: South Korea - Number of Male Breast Cancer Cases & Deaths, 2016
  • Figure 2-65: South Korea - Age Specific Incidence Rate of Breast Cancer (Per 100,000 People), 2016, 2018 & 2025
  • Figure 2-66: South Korea - Age Specific Mortality Rate of Breast Cancer (Per 100,000 People), 2016 & 2018
  • Figure 2-67: South Korea - 5 Year Survival Rate of Male & Female Breast Cancer (%), 2012-2016
  • Figure 2-68: South Korea - Breast Cancer Cases by Stage (%), 2015
  • Figure 2-69: Australia - Newly Diagnosed Breast Cancer Cases, 2018, 2019 & 2025
  • Figure 2-70: Australia - Breast Cancer Related Deaths, 2018 & 2019
  • Figure 2-71: Australia - Breast Cancer Cases vs. Other Cancers in Females, 2018
  • Figure 2-72: Australia - Breast Cancer Cases - Male & Female, 2019
  • Figure 2-73: Australia - Breast Cancer Deaths - Male & Female, 2019
  • Figure 2-74: Australia - Age Specific Breast Cancer Incidence & Death Rate, 2018
  • Figure 2-75: Australia - 5 year & 10 Year Survial Rate of Breast Cancer
  • Figure 2-76: Australia - Probability of Breast Cancer in Males & Females (%), 2018
  • Figure 3-1: Hormonal Therapy for Breast Cancer Treatment
  • Figure 3-2: Commercially Available Aromatase Inhibitors Drugs for Breast Cancer Management
  • Figure 3-3: Commercially Available Estrogen Receptor Antagonist Drugs for Breast Cancer Management
  • Figure 3-4: Commercially Available SERMs for Breast Cancer Management
  • Figure 3-5: Commercially Available Gonadotropin Releasing Hormone Analogues for Breast Cancer Management
  • Figure 3-6: Role of CDK 4/6 Inhibitors in Different Types of Breast Cancer
  • Figure 3-7: Types of HER2 Inhibitors for Breast Cancer Management
  • Figure 3-8: Commercially Available HER2 Targeting Monoclonal Antibodies for Breast Cancer
  • Figure 3-9: Commercially Available mTOR & PI3K Inhibitors for Breast Cancer Treatment
  • Figure 3-10: Commercially Available mTOR & PI3K Inhibitors for Breast Cancer Treatment
  • Figure 3-11: Commercially Available Immune Checkpoint Inhibitors for Breast Cancer Treatment
  • Figure 3-12: Commercially Available Mitotic/Microtubule Inhibitors for Breast Cancer Treatment
  • Figure 3-13: Commercially Available EGFR Inhibitors for Breast Cancer Treatment
  • Figure 4-1: Breast Cancer Related Active Clinical Trials - Total vs. Metastatic Breast Cancer Studies, October'2019
  • Figure 4-2: Discontinued Breast Cancer Trials - Suspended, Terminated & Withdrawn Trials, October'2019
  • Figure 4-3: Number of Discontinued, Completed & Unknown Status Clinical Studies, October 2019
  • Figure 4-4: Number of Clinical Trials by Treatment, October'2019
  • Figure 4-5: Number of Clinical Trials Related to Different Targeted Therapeutics, October'2019
  • Figure 4-6: Number of CDK 4/6 Inhibitors Related Clinical Trials against Breast Cancer, October'2019
  • Figure 4-7: Number of New CDK 4/6 Inhibitors in Different Phases of Clinical Trial, October'2019
  • Figure 4-8: New CDK inhibitors in Different Phases of Clinical Trial (%), October'2019
  • Figure 4-9: Hormonal Therapeutics Related Clinical Trials against Breast Cancer, October'2019
  • Figure 4-10: Number of PARP Inhibitors Related Clinical Trials against Breast Cancer, October'2019
  • Figure 4-11: Number of Other Targeted Therapy Related Clinical Trials against Breast Cancer, October'2019
  • Figure 4-12: Number of Vaccine & Immunotherapeutic Related Clinical Trials against Breast Cancer, October'2019
  • Figure 4-13: Number of HER2 Inhibitors Related Clinical Trials against Breast Cancer, October'2019
  • Figure 5 1: Global - Breast Cancer Clinical Pipeline by phase (Number), 2020 till 2025
  • Figure 5-2: Global - Breast Cancer Clinical Pipeline by phase (%), 2020 till 2025
  • Figure 5-3: Global - Breast Cancer Drug Pipeline by Region (Number), 2020 till 2025
  • Figure 5-4: Global - Breast Cancer Drug Pipeline by Country (Number), 2020 till 2025
  • Figure 5-5: Global - Breast Cancer Drug Pipeline by Biomarker (Number), 2020 till 2025
  • Figure 5-6: Global - Breast Cancer Drug Pipeline by Formulation (Number), 2020 till 2025
  • Figure 5-7: Global - Breast Cancer Drug Pipeline by Country (Number), 2020 till 2025
  • Figure 5-8: Global - Breast Cancer Drug Pipeline by Mechanism (Number), 2020 till 2025
  • Figure 6-1: Global Breast Cancer Drug Pipeline - Share of Unknown Phase in Total Clinical Pipeline (%), 2020 till 2025
  • Figure 7-1: Global Breast Cancer Drug Pipeline - Share of Research Phase in Total Clinical Pipeline (%), 2020 till 2025
  • Figure 8-1: Global Breast Cancer Drug Pipeline - Share of Preclinical Phase in Total Clinical Pipeline (%), 2020 till 2025
  • Figure 9-1: Global Breast Cancer Drug Pipeline - Share of Clinical Phase in Total Clinical Pipeline (%), 2020 till 2025
  • Figure 10-1: Global Breast Cancer Drug Pipeline - Share of Phase-I Phase in Total Clinical Pipeline (%), 2020 till 2025
  • Figure 11-1: Global Breast Cancer Drug Pipeline - Share of Phase-I/II Phase in Total Clinical Pipeline (%), 2020 till 2025
  • Figure 12-1: Global Breast Cancer Drug Pipeline - Share of Phase-II Phase in Total Clinical Pipeline (%), 2020 till 2025
  • Figure 13-1: Global Breast Cancer Drug Pipeline - Share of Phase-II/III Phase in Total Clinical Pipeline (%), 2020 till 2025
  • Figure 14-1: Global Breast Cancer Drug Pipeline - Share of Phase-III Phase in Total Clinical Pipeline (%), 2020 till 2025
  • Figure 15-1: Global Breast Cancer Drug Pipeline - Share of Preregistration Phase in Total Clinical Pipeline (%), 2020 till 2025
  • Figure 16-1: Global Breast Cancer Drug Pipeline - Share of Registration Phase in Total Clinical Pipeline (%), 2020 till 2025
目次

"Global Breast Cancer Drug Market & Clinical Trial Insight 2025" Report Highlights:

  • Global Breast Cancer Drug Market: US$ 40 Billion Opportunity
  • Global Breast Cancer Drug Clinical Pipeline: More Than 550 Drugs
  • Marketed Breast Cancer Drugs: More Than 90 Drugs
  • Comprehensive Clinical Insight & Patent Information
  • Drug Trials, Pricing, Dosage, Cancer Prevalence Insight: 130 Graphs/Charts

The applied science research has marked tremendous advancements in cutting off the epidemic cancer scenarios all around the world but every year unexpectedly more than one million new cases of breast cancer are reported. Breast cancer is somehow responsible for accounting about 10% of all the cancer cases worldwide. Although there has been a limitation in the treatment facilities for cancer cases but since few years there has been an excellent increase in the awareness level with regarding its impact on the survival rates in the case of early diagnosis of breast cancer.

"Global Breast Cancer Drug Market Offers US$ 40 Billion Market Opportunity Across Multiple Drug Classes Like Vaccines, Antibodies, Small Molecule, Peptides, Radiopharmaceuticals etc."

The increasing cases of breast cancer have however opened a very prominent and novel opportunity for the market of breast cancer all over the world. Several therapies and products gets marketed under the category of breast cancer treatment market and some of these products or therapies include: chemotherapies, targeted therapies, hormonal therapies and many more. The unmet needs with respect to unconvincing safety data and severe adverse effects are however enhancing the realistic opportunities for the expansion of breast cancer drug market focused on improved efficacy and safety. The factors such as improved safety and efficacy are demanding the primary research focus from the R&D groups of the pharmaceutical companies.

“The pharmaceutical R&D groups are compelled to effectively unravel and understand the key dynamics of the market, competitive market, pipeline of the drug and the market forecast to better provide a realistic perspective of the market of breast cancer”

The participation of several major key players majorly towards the research and development of novel drugs is expected to develop the market of breast cancer drugs lucratively in the coming years. On an average, the engagement of the extensive research groups in developing the drugs for breast cancer calls for an unpredictable table of opportunities for them as well as the patients. The inevitable advancements with respect to customization and designing and the strong pipeline of the therapeutic agents are proving to be an effective treatment option than the already existing therapies.

High awareness, well established healthcare infrastructure are some of the factors that are however responsible for covering a large market share and owing to this, North America since few years is capable of holding the largest market share of global breast cancer drug market. Growing research and development investments and increasing incidence of breast cancer is adding to the conclusion that Europe is among the second largest market share of the global breast cancer drug market. Countries of Asia-Pacific are expected to be among the new additions for the breast cancer drug market in the next few years.

According to research report findings, the global breast cancer drug market is expected to rise upto many folds. Report gives in depths insight on multiple perspective of the breast cancer drug market and ongoing clinical trials. Each section of the report offers a deep insight view about the current market data, market drivers, trends and opportunities, drugs that are top-selling, major key players and the competitive outlook related to the market.

The data presented in the report covers all the market trends of the various geographic regions and the robust drug pipeline being followed by the country. In addition to this, the report also successfully provides the profile of the major companies participating in the development of the market. The secondary research included in the report is progressed through unpaid sources and open journals. The breast cancer drug market is expected to witness positive outlook in future driven by strong pipeline of drug candidates in clinical trials and availability of wide spectrum of drugs in the market.

Table of Contents

1. Introduction to Breast Cancer Drug Market

  • 1.1 Overview
  • 1.2 Historical Development of Breast Cancer Drugs

2. Global Breast Cancer Prevalence & Statistics

  • 2.1 North America
    • 2.1.1 United States
    • 2.1.2 Canada
  • 2.2 Europe
    • 2.2.1 United Kingdom
    • 2.2. Germany
    • 2.2.3 Russia
  • 2.3 Asia-Pacific
    • 2.3.1 China
    • 2.3.2 India
    • 2.3.3 Japan
    • 2.3.4 South Korea
    • 2.3.5 Australia

3. Available Therapeutics for Breast Cancer Management

  • 3.1 Hormonal Therapy
    • 3.1.1 Aromatase Inhibitors
    • 3.1. Estrogen Receptor Antagonist
    • 3.1.3 Selective Estrogen Receptor Modulators (SERMs)
    • 3.1.4 Gonadotropin Releasing Hormone Drugs
  • 3.2 CDK 4/6 Inhibitors
  • 3.3 HER2 Inhibitors
    • 3.3.1 Monoclonal antibodies
    • 3.3.2 Tyrosine Kinase Inhibitor
  • 3.4 PI3K & mTOR Inhibitors
  • 3.5 PARP Inhibitors
  • 3.6 Other Therapeutics
    • 3.6.1 Immune Checkpoint Inhibitors
    • 3.6.2 Mitotic / Microtubule Inhibitors
    • 3.6.3 EGFR Inhibitors

4. Breast Cancer Therapeutics Clinical Insight

  • 4.1 Overview
  • 4.2 Breast Cancer's Clinical Trials by Drug Class & Phase
    • 4.2.1 CDK 4/6 Inhibitors Related Trials
    • 4.2.2 Hormonal Therapy Related Clinical Trials
    • 4.2.3 PARP Inhibitors Related Clinical Trials
    • 4.2.4 Other Targeted Therapeutic Related Clinical Trials
    • 4.2.5 Vaccines & Immunotherapeutics Related Clinical Trials
    • 4.2.6 HER2 Inhibitors Related Clinical Trials

5. Global Breast Cancer Drug Clinical Pipeline Insight

  • 5.1 By Phase
  • 5.2 By Country/Region
  • 5.3 By Biomarker
  • 5.4 By Formulation
  • 5.5 By Company
  • 5.6 By Mechanism

6. Global Breast Cancer Drug Clinical Trial Insight: Unknown

  • 6.1 Overview
  • 6.2 Clinical Pipeline Insight

7. Global Breast Cancer Drug Clinical Trial Insight: Research Phase

  • 7.1 Overview
  • 7.2 Clinical Pipeline Insight

8. Global Breast Cancer Drug Clinical Trial Insight: Preclinical Phase

  • 8.1 Overview
  • 8.2 Clinical Pipeline Insight

9. Global Breast Cancer Drug Clinical Trial Insight: Clinical Phase

  • 9.1 Overview
  • 9.2 Clinical Pipeline Insight

10. Global Breast Cancer Drug Clinical Trial Insight: Phase-I

  • 10.1 Overview
  • 10.2 Clinical Pipeline Insight

11. Global Breast Cancer Drug Clinical Trial Insight: Phase-I/II

  • 11.1 Overview
  • 11.2 Clinical Pipeline Insight

12. Global Breast Cancer Drug Clinical Trial Insight: Phase-II

  • 12.1 Overview
  • 12.2 Clinical Pipeline Insight

13. Global Breast Cancer Drug Clinical Trial Insight: Phase-II/III

  • 13.1 Overview
  • 13.2 Clinical Pipeline Insight

14. Global Breast Cancer Drug Clinical Trial Insight: Phase-III

  • 14.1 Overview
  • 14.2 Clinical Pipeline Insight

15. Global Breast Cancer Drug Clinical Trial Insight: Preregistration

  • 15.1 Overview
  • 15.2 Clinical Pipeline Insight

16. Global Breast Cancer Drug Clinical Trial Insight: Registered

  • 16.1 Overview
  • 16.2 Clinical Pipeline Insight

17. Marketed Breast Cancer Drug Clinical Insight by Company

18. Competitive Landscape

  • 18.1 Novartis
  • 18.2 Amgen
  • 18.3 Eli Lilly
  • 18.4 Merck
  • 18.5 Pfizer
  • 18.6 GlaxoSmithKline
  • 18.7 Roche
  • 18.8 Takeda Pharmaceuticals
  • 18.9 Teva Pharmaceuticals
  • 18.10 AstraZeneca
  • 18.11 G1 Therapeutics
  • 18.12 Nerviano Medical Science
  • 18.13 Genentech
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.